Home    Back

Ccx140-b    (DrugBank: CCX-140)

1 disease
IDDisease name (Link within this page)Number of trials
222Primary nephrotic syndrome7

222. Primary nephrotic syndrome    [ 234 clinical trials,   241 drugs,   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways]
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 234 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2017-003022-32-PL
(EUCTR)		12/10/201920/08/2019An open, dose escalation study in patients with Primary Focal Segmental Glomerulosclerosis (FSGS - a type of glomerular disease causes scarring in the kidney) and Nephrotic Syndrom (collection of symptoms due to kidney damage)An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome Primary Focal Segmental Glomerulosclerosis (FSGS)
MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Code: CCX140-B
INN or Proposed INN: not available yet		ChemoCentryx, Inc.NULLNot RecruitingFemale: yes
Male: yes		13Phase 2United States;France;Canada;Poland;United Kingdom
2EUCTR2017-003021-15-GB
(EUCTR)		23/10/201814/03/2018A study in which the safety and efficacy of CCX140-B is compared with placebo in patients with Focal Segmental GlomerulosclerosisA Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) Focal Segmental Glomerulosclerosis (FSGS)
MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Code: CCX140-BChemoCentryx, Inc.NULLNot RecruitingFemale: yes
Male: yes		40Phase 2France;United States;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom
3NCT03703908
(ClinicalTrials.gov)		October 1, 201824/7/2018A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic SyndromeAn Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic SyndromeFocal Segmental GlomerulosclerosisDrug: CCX140-BChemoCentryxNULLRecruiting18 YearsN/AAll13Phase 2United States
4EUCTR2017-003021-15-IT
(EUCTR)		04/07/201810/11/2020A study to evaluate the efficacy og CCX140-B in patients with FSGSA Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) - NA Focal Segmental Glomerulosclerosis (FSGS)
MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: -
Product Code: [CCX140-B]		CHEMOCENTRYX, INC.NULLNot RecruitingFemale: yes
Male: yes		40Phase 2United States;France;Czechia;Canada;Poland;Australia;Germany;United Kingdom;New Zealand;Italy
5EUCTR2017-003021-15-PL
(EUCTR)		19/06/201818/05/2018A controlled study to evaluate the safety and efficacy of the study drug, CCX140-B, in subjects with Focal Segmental Glomerulosclerosis (a type of glomerular disease)A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) Focal Segmental Glomerulosclerosis (FSGS)
MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Code: CCX140-B
INN or Proposed INN: INN not available yet		ChemoCentryx, Inc.NULLNot RecruitingFemale: yes
Male: yes		40Phase 2France;United States;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2017-003021-15-FR
(EUCTR)		18/05/201813/03/2018Study to determine the dose CCX140-B and to evaluate the its safety and efficacy of in Subjects with Focal Segmental Glomerulosclerosis (FSGS)A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) Focal Segmental Glomerulosclerosis (FSGS)
MedDRA version: 20.0;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Code: CCX140-BChemoCentryx, Inc.NULLNot RecruitingFemale: yes
Male: yes		40Phase 2United States;France;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom
7NCT03536754
(ClinicalTrials.gov)		May 1, 201828/3/2018A Study of CCX140-B in Subjects With FSGSA Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)FSGS;Focal Segmental Glomerulosclerosis;GlomerulosclerosisOther: Placebo;Drug: CCX140-BChemoCentryxMedpace, Inc.Active, not recruiting18 Years75 YearsAll46Phase 2United States;Australia;Canada;France;Italy;New Zealand;Poland;United Kingdom

Back to top